Atria Investments Inc Takes Position in ICU Medical, Inc. (NASDAQ:ICUI)

Atria Investments Inc bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,251 shares of the medical instruments supplier’s stock, valued at approximately $228,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Innealta Capital LLC acquired a new stake in ICU Medical in the 2nd quarter worth $32,000. Hexagon Capital Partners LLC grew its position in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 122 shares in the last quarter. Allworth Financial LP increased its stake in ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 100 shares during the period. EntryPoint Capital LLC raised its holdings in ICU Medical by 731.5% in the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after acquiring an additional 395 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 173 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,096,771.78. This represents a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This represents a 16.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,502 shares of company stock valued at $6,573,496. Corporate insiders own 6.70% of the company’s stock.

ICU Medical Stock Down 0.2 %

ICUI opened at $168.46 on Friday. The firm has a market cap of $4.12 billion, a price-to-earnings ratio of -36.86 and a beta of 0.66. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The firm’s 50-day simple moving average is $176.22 and its 200-day simple moving average is $145.40. ICU Medical, Inc. has a twelve month low of $83.26 and a twelve month high of $196.26.

Analyst Ratings Changes

Several analysts have recently weighed in on ICUI shares. Jefferies Financial Group started coverage on ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. KeyCorp boosted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. Finally, Raymond James increased their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $173.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.